Rich Pharmaceuticals’ Study Drug RP-323 (TPA) Elevates White Blood Cells (WBCs) Which Play a Vital Role Fighting … – GlobeNewswire (press release)
|
Rich Pharmaceuticals' Study Drug RP-323 (TPA) Elevates White Blood Cells (WBCs) Which Play a Vital Role Fighting …
GlobeNewswire (press release) BEVERLY HILLS, CA, March 06, 2018 (GLOBE NEWSWIRE) — Rich Pharmaceuticals, Inc. (OTC: RCHA), is a Biopharmaceutical Company focused on developing and commercializing innovative therapies in oncology using its study drug RP-323 (TPA). Multiple clinical … |
